GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics Inc (NAS:SMMT) » Definitions » Shares Outstanding (EOP)

SMMT (Summit Therapeutics) Shares Outstanding (EOP) : 741.61 Mil (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Summit Therapeutics Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Summit Therapeutics's shares outstanding for the quarter that ended in Mar. 2025 was 741.61 Mil.

Summit Therapeutics's quarterly shares outstanding increased from Dec. 2024 (737.63 Mil) to Mar. 2025 (741.61 Mil). It means Summit Therapeutics issued new shares from Dec. 2024 to Mar. 2025 .

Summit Therapeutics's annual shares outstanding increased from Dec. 2023 (701.66 Mil) to Dec. 2024 (737.63 Mil). It means Summit Therapeutics issued new shares from Dec. 2023 to Dec. 2024 .


Summit Therapeutics Shares Outstanding (EOP) Historical Data

The historical data trend for Summit Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Shares Outstanding (EOP) Chart

Summit Therapeutics Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23 Dec24
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 82.58 98.04 211.09 701.66 737.63

Summit Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 701.98 724.32 737.10 737.63 741.61

Competitive Comparison of Summit Therapeutics's Shares Outstanding (EOP)

For the Biotechnology subindustry, Summit Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Summit Therapeutics's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Summit Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Summit Therapeutics's Shares Outstanding (EOP) falls into.


;
;

Summit Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Summit Therapeutics  (NAS:SMMT) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Summit Therapeutics Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Summit Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
601 Brickell Key Drive, Suite 1000, Miami, FL, USA, 33131
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Executives
Maky Zanganeh director 51 ADAM WAY, ATHERTON CA 94027
Ankur Dhingra officer: Chief Financial Officer C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Manmeet Singh Soni director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Robert W Duggan director, 10 percent owner, officer: See Remarks 611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Yu Xia director 6 SHENNONG ROAD, TORCH DEVELOPMENT ZONE, ZHONGSHAN, GUANGDONG F4 528437
Robert F. Booth director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Alessandra Cesano director 700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Urte Gayko director C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Kenneth A Clark director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Jeffrey R Maranian officer: VP, Corporate Controller C/O SUMMIT THERAPEUTICS INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Luhua Wang director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
David Jonathan Powell officer: Chief Scientific Officer ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Camilla Graham officer: Chief Clinical Affairs Officer ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ventzislav Stefanov director, officer: See Remarks ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ujwala Mahatme director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142